Franklin Resources Inc. Has $104.95 Million Stock Holdings in Praxis Precision Medicines, Inc. $PRAX

Franklin Resources Inc. lifted its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) by 13.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 356,074 shares of the company’s stock after acquiring an additional 41,917 shares during the period. Franklin Resources Inc. owned approximately 1.41% of Praxis Precision Medicines worth $104,949,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Arizona State Retirement System bought a new stake in Praxis Precision Medicines during the 3rd quarter worth approximately $287,000. Vanguard Group Inc. increased its stake in Praxis Precision Medicines by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,267,286 shares of the company’s stock worth $67,166,000 after purchasing an additional 51,642 shares in the last quarter. Rafferty Asset Management LLC increased its stake in Praxis Precision Medicines by 51.5% during the 3rd quarter. Rafferty Asset Management LLC now owns 37,573 shares of the company’s stock worth $1,991,000 after purchasing an additional 12,768 shares in the last quarter. Algert Global LLC increased its stake in Praxis Precision Medicines by 483.3% during the 3rd quarter. Algert Global LLC now owns 160,818 shares of the company’s stock worth $8,523,000 after purchasing an additional 133,248 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new stake in Praxis Precision Medicines during the 4th quarter worth approximately $977,000. 67.84% of the stock is currently owned by institutional investors and hedge funds.

Praxis Precision Medicines Trading Down 3.9%

NASDAQ:PRAX opened at $240.66 on Thursday. Praxis Precision Medicines, Inc. has a 1-year low of $37.19 and a 1-year high of $366.52. The firm has a fifty day simple moving average of $321.86 and a 200 day simple moving average of $300.26. The stock has a market capitalization of $6.71 billion, a PE ratio of -18.00 and a beta of 2.71.

Praxis Precision Medicines (NASDAQ:PRAX) last released its earnings results on Thursday, May 7th. The company reported ($3.20) earnings per share for the quarter, beating the consensus estimate of ($3.58) by $0.38. On average, equities analysts predict that Praxis Precision Medicines, Inc. will post -14.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

PRAX has been the subject of a number of research reports. Wedbush lowered their target price on Praxis Precision Medicines from $166.00 to $162.00 and set an “underperform” rating for the company in a research note on Tuesday, June 2nd. Wells Fargo & Company set a $305.00 target price on Praxis Precision Medicines and gave the stock an “equal weight” rating in a research note on Friday, February 20th. BTIG Research reissued a “buy” rating and set a $810.00 target price (down from $843.00) on shares of Praxis Precision Medicines in a research note on Tuesday, June 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Praxis Precision Medicines in a research note on Thursday, May 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $650.00 price target (down from $750.00) on shares of Praxis Precision Medicines in a research note on Tuesday, June 2nd. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Praxis Precision Medicines currently has an average rating of “Moderate Buy” and an average target price of $572.72.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.